Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term momentum without new products.

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech traded blows this week with rival Moderna as dueling decisions came down in | Moderna sued Pfizer and BioNTech over three patents protecting its COVID-19 work back in 2022.

Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top executives said.

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases

The S&P 500 advanced 1.1% on Wednesday, March 5, as the White House announced it would delay tariffs affecting U.S. automakers.

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read more here.

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of investors to put into their portfolios. Taking a wait-and-see approach may be the safest option today.

Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with five new international lawsuits. | The companies claim that Moderna stepped on their lipid nanoparticle technology with its COVID vaccine Spikevax and RSV vaccine mRESVIA.